Core Insights - Biomerica, Inc. has announced the publication of a large multicenter clinical trial demonstrating the effectiveness of its inFoods® IBS diagnostic-guided therapy in managing Irritable Bowel Syndrome (IBS) symptoms [1][3][10] Study Overview - The clinical trial was randomized, multicenter, double-blind, and placebo-controlled, evaluating the inFoods® IBS test's ability to identify patient-specific dietary triggers and guide targeted food elimination [2][4] - The study involved 223 IBS patients across eight major U.S. academic medical centers, including renowned institutions like Mayo Clinic and Harvard Beth Israel Deaconess Medical Center [4] Key Findings - Patients following the inFoods® IBS-guided elimination diet experienced significantly greater symptom relief, with 59.6% achieving the FDA-defined target for abdominal pain reduction compared to 42.1% in the control group [9] - Particularly strong results were noted in difficult-to-treat IBS subtypes, with 67.1% of IBS-C patients and 66.0% of IBS-M patients responding positively to the treatment [9] Methodology and Innovation - The inFoods® IBS assay utilizes a proprietary discriminatory p-value method to identify foods causing abnormal IgG responses unique to IBS patients, allowing for a more focused dietary approach [7][10] - The study design addressed limitations of previous research by employing an IBS-specific food panel and robust statistical methodology, enhancing the reliability of the findings [6][10] Clinical Implications - The results support a shift towards precision medicine in gastrointestinal care, where individualized biological markers guide tailored treatment decisions rather than generalized approaches [12][11] - The inFoods® IBS protocol typically results in the elimination of only 2 to 4 foods per patient, making it a more practical and sustainable option compared to broader dietary strategies like the low-FODMAP diet [8][10] Recognition and Future Outlook - The inclusion of inFoods® IBS in Biotherapeutics Quarterly highlights the growing recognition of Biomerica's innovation among healthcare professionals [13] - The study's outcomes underscore the potential of diagnostic-guided dietary strategies to address unmet clinical needs, particularly for IBS-M patients, for whom no FDA-approved medications currently exist [11][12]

Core Insights - Biomerica Inc. has appointed Gary Huff as an independent board member, bringing extensive leadership experience in the diagnostics and healthcare services industry [1][2][3] - Mr. Huff's background includes serving as CEO of LabCorp Diagnostics and managing commercial laboratories across various sizes and sectors, contributing to sustainable growth and operational efficiencies [2][3] - Biomerica's innovative product, inFoods® IBS, aims to transform the management of irritable bowel syndrome (IBS) by identifying patient-specific food triggers [3][4] Company Overview - Biomerica, Inc. is a global biomedical technology company focused on developing, patenting, manufacturing, and marketing advanced diagnostic and therapeutic products for medical conditions, particularly gastrointestinal and inflammatory diseases [10] - The company aims to enhance health and well-being while reducing healthcare costs through its diagnostic solutions [10] Product Insights - inFoods® IBS is a diagnostic-guided therapy that utilizes a finger-stick blood sample to identify food triggers for IBS symptoms, allowing for targeted dietary changes [4][9] - A recent clinical trial published in June 2025 demonstrated that 59.6% of patients in the treatment group achieved significant abdominal pain reduction compared to 42.1% in the control group, indicating the product's potential effectiveness [5][8] Leadership and Strategic Vision - Gary Huff's appointment is expected to provide valuable insights as Biomerica expands its market presence and enhances its innovative diagnostic portfolio [3] - Mr. Huff has a proven track record in building successful diagnostics businesses and delivering shareholder value, which aligns with Biomerica's growth objectives [2][3]